Kyverna Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Kyverna Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $124.09 million for the year ending 2025.

  • Kyverna Therapeutics, Inc. showed an increase of +28.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Kyverna Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
  • XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 3 years of available data (2023 to 2025), Kyverna Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 258.2%.
  • Historical annual values: Fiscal year 2025: $124.09 million | Fiscal year 2024: $96.62 million | Fiscal year 2023: $34.65 million.
  • Data sourced from SEC EDGAR public filings as of June 24, 2026.

Last verified: